Mobile website
Expression of somatostatin receptor subtypes and epidermal growth factor receptor in nonsmall cell lung cancer and their clinical significance
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
To investigate the expression of somatostatin receptors (SSTR) subtypes (SSTTR2A, and SSTR5) and epidermal growth factor receptor (EGFR) in nonsmall cell lung cancer (NSCLC) and their clinical relevance. Methods: The expressions of SSTR2A, SSTR5, and EGFR in 62 NSCLC specimens and 7 adjacent normal lung tissues were examined using immunohistochemical method (SP). All patients were followed up in this study. Results: The positive rates of SSTR2A and SSTR5 in the 62 specimens were 48.3% (30 cases) and 70.9% (44 cases), respectively. The positive rates of SSTR2A and SSTR5 were closely related to TNM stage (P<0.05), but not to patients' ages, sexes, smoking history, pathological types, tumor sizes, and lymph metastases (P>0.05). In the same group, EGFR expressed in 56.4% (35 cases) of NSCLC specimens, but was not expressed in the 7 normal spesimens. The positive rate of EGFR was not related to the ages, sexes, smoking history, histological types, tumor sizes, TNM stages, pathological classification, and lymph metastases (P>0.05). There was a negative correlation between the EGFR expression with the expression of SSTR2A and SSTR5 in NSCLC tissues. The 3year survival rates were 64.5% and 65.9% in patients positive of SSTR5 and SSTR2A, respectively; and were 45.2% and 22.2% for those negative of SSTR5 and SSTR2A, respectively (P<0.05). The 3year survival rate was 30.8% for patients positive of EGFR protein and 69.4% for those negative of it (P<0.05). Conclusion: The expressions of SSTR2A, SSTR5, and EGFR can reflect the biology behavior of lung cancer, and the examination of them may be helpful for evaluation of the lymph node metastases, pathological classification, and prognosis of NSCLC.
Keywords:
Project Supported:
Clc Number:
R373.9 R730.5
